Multi-Institutional Analysis of Patients Undergoing Proton Re-Irradiation for de novo or Recurrent Malignancies of the Esophagus
Cristina DeCesaris(University of Maryland, Baltimore), Jason K. Molitoris(University of Maryland, Baltimore), R.S. Bhangoo(Mayo Clinic Hospital), C. Ryan Miller(University of North Carolina at Chapel Hill), Terence T. Sio(The University of Texas MD Anderson Cancer Center), Ranee Mehra(University of Maryland, Baltimore), Christopher L. Hallemeier(Mayo Clinic in Arizona), Allison E. Garda(Mayo Clinic in Arizona), Tyler Gutschenritter(University of Washington), Smith Apisarnthanarax(University of Washington)
International Journal of Radiation Oncology*Biology*Physics
October 23, 2020
Cited by 1
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
|Journal of Clinical Oncology|2011|551